Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 555Neoplasms 501Carcinoma, Non-Small-Cell Lung 416Prostatic Neoplasms 327Colorectal Neoplasms 311Lung Neoplasms 276Neoplasm Metastasis 234Leukemia, Myeloid, Acute 211Ovarian Neoplasms 205Pancreatic Neoplasms 190Multiple Myeloma 185Recurrence 140Squamous Cell Carcinoma of Head and Neck 138Stomach Neoplasms 137Brain Neoplasms 135Melanoma 133Carcinoma, Hepatocellular 132Endometrial Neoplasms 127Glioblastoma 123Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 116Head and Neck Neoplasms 102Hematologic Neoplasms 101Carcinoma, Renal Cell 101Urinary Bladder Neoplasms 97Lymphoma 97Sarcoma 94Glioma 92Esophageal Neoplasms 89Uterine Cervical Neoplasms 85

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Atypical Hemolytic Uremic Syndrome × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔